[go: up one dir, main page]

AR040411A1 - Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan - Google Patents

Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan

Info

Publication number
AR040411A1
AR040411A1 AR20030101630A ARP030101630A AR040411A1 AR 040411 A1 AR040411 A1 AR 040411A1 AR 20030101630 A AR20030101630 A AR 20030101630A AR P030101630 A ARP030101630 A AR P030101630A AR 040411 A1 AR040411 A1 AR 040411A1
Authority
AR
Argentina
Prior art keywords
nhc
integer
aryl
group
cycloalkyl
Prior art date
Application number
AR20030101630A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR040411A1 publication Critical patent/AR040411A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un método para inhibir la actividad de la polimerasa de VHC caracterizado porque comprende poner en contacto una polimerasa VHC con una cantidad eficaz de un compuesto representado por la fórmula (1) o una sal, solvato, profármaco, o metabolito del mismo; en la que r es 0, 1, 2, 3, 4 o 5; R1 es hidrógeno, o un grupo arilo, heteroarilo, cicloalquilo, o heterocicloalquilo, sin substituir o substituido con uno o más substituyentes seleccionados entre el grupo substituir o substituido con uno o más substituyentes seleccionados entre el grupo compuesto por grupos halógenos; =O; =S; -CN; -NO2; alcano ramificado o no ramificado; alquilo; heteroalquilo; alquenilo; alquinilo; arilo; cicloalquilo; heterocicloalquilo; heteroarilo; compuesto por halógeno; =O; =S; -CN; -NO2; alquilo; heteroalquilo; alquenilo; alquinilo; arilo; cicloalquilo; heterocicloalquilo; heteroarilo; alcoxi; isopropilo; t-butilo; -(CH2)zCN donde z es un entero de 1 a 4; =NH; -NHOH; -OH; -OCH3; -OCH2-; -OCH2CH3; -C(O)H; -OC(O)H; -C(O)OH; -CH2CH(O)OCH3; -OC(O)OH; -OC(O)OC(O)H; -OOH; -C(NH)NH2; -NHC(NH)NH2; -C(S)NH2; -NHC(S)NH2; -NHC(O)NH2; -S(O2)H; -S(O)H; -NH2; -C(O)NH2; -OC(O)NH2; -NHC(O)H; -NHC(O)OH; -C(O)NHC(O)H; -OS(O2)H; -OS(O)H; -OSH; -SC(O)H; -S(O)C(O)OH; -SO2C(O)OH; -SO2CH3; -NHSH; -NHS(O)H; -NHSO2H; -C(O)SH; -C(O)S(O)H; -C(O)S(O2)H; -C(S)OH; -C(SO)OH; -C(SO2)OH; -NHC(S) H; -OC(S)H; -OC(S)OH; -OC(SO2)H; -S(O2)NH2; -S(O)NH2; -SNH2; -NHCS(O2)H; -NHC(SO)H; -NHC(S)H; y -SH, sin alcoxi; -(CH2)zCN donde z es un entero de 1 a 4; =NH; -NHOH; -OH; -C(O)H; -OC(O)H; -C(O)OH; -C(O)OC(CH3)n, donde n es un entero de 1 a 3; -OC(O)OH; -OC(O)OC(O)H; -OOH; -C(NH)NH2; -NHC(NH)NH2; -C(S)NH2; -NHC(S)NH2; -NHC(O)NH2; -S(O2)H; -S(O)H; -NH2; -C(O)NH2; -OC(O)NH2; -NHC(O)H; -NHC(O)OH; -C(O)NHC(O)H; -OS(O2)H; -OS(O)H; -OSH; -SC(O)H; -SCH2CH3; -S(O)C(O)OH; -SO2C(O)OH; -NHSH; -NHS(O)H; -NHSO2H; -C(O)SH; -C(O)S(O)H; -C(O)S (O2)H; -C(S)H; -C(SO)OH; -C(SO2)OH; -NHC(S)H; -OC(S)H; -OC(S)OH; -OC(SO2)H; -S(O2)NH2; -S(O)NH2; -SNH2; -NHCS(O2)H; -NHC(SO)H; -NHC(S)H; y -SH sin substituir o substituidos con uno o más substituyentes seleccionados entre el grupo compuesto por halógenos; fenilo; cicloalcano; -O-; -OH; y CH3; R2 es un grupo isopropilo, ciclopentilo, o ciclohexilo, sin substituir o substituido con uno o más substituyentes seleccionados entre el grupo compuesto por halógenos; =O; =S; -CN; -NO2; alquilo; alquenilo; alquinilo; arilo; cicloalquilo; heterocicloalquilo; heteroarilo; -(CH2)zCN donde z es un entero de 1 a 4; =NH; -NHOH; -OH; -C(O)H; -OC(O)H; -C(O)OH; -OC(O)OH; -OC(O)OC(O)H; -OOH; -C(NH)NH2; -NHC(NH)NH2; -C(S)NH2; -NHC(S)NH2; -NHC(O)NH2; -S(O2)H; -S(O)H; -NH2; -C(O)NH2; -OC(O)NH2; -NHC(O)H; -NHC(O)OH; -C(O)NHC(O)H; OS(O2)H; -OS(O)H; -OSH; -SC(O)H; -S(O)C(O)OH; -SO2C(O)OH; -NHSH; -NHS(O)H; -NHSO2H; -C(O)SH; -C(O)S(O)H; -C(O)S(O2)H; -C(S)OH; -C(SO)OH; -C(SO2)OH; -NHC(S)H; -OC(S)H; -OC(S)OH; -OC(SO2)H; -S(O2)NH2; -S(O)NH2; -SNH2; -NHCS (O2) H; -NHC(SO)H; -NHC(S)H; y -SH; R3 es hidrógeno; halógeno; =S; -SH; -S-(CH2)z-heteroarilo donde z es un entero de 0 a 4; -S-(CH2)z-heterocicloalquilo donde z es un entero de 0 a 4; -S-(CH2)z-arilo donde z es un entero de 0 a 4; -(CH2)z-arilo donde z es un entero de 0 a 4; -O-arilo; -C(O)H; -C(O)-alquilo; amino; o un halógeno, sin substituir o substituido con un grupo arilo, halógenos; =O; =S; -CN; -NO2; alquilo; heteroalquilo; alquenilo; alquinilo; arilo; cicloalquilo; heterocicloalquilo; heteroarilo; alcoxi; isopropilo; t-butilo; - (CH2)zCN donde z es un entero de 1 a 4; =NH; -NHOH; -OH; -OCH3, -OCH2-; -OCH2CH3; -C(O)H; -OC(O)H; -C(O)OH; -OS(O2)H; -OS(O)H; -OSH; -SC(O)H; -S(O)C(O)OH; -SO2C(O)OH; -SO2CH3; -NHSH; -NHS(O)H; -NHSO2H; -C(O)SH; -C(O)S(O)H; -C(O)S(O2)H; -C(S)OH; -C(SO)OH; -C(SO2)OH; -NHC(S)H; -OC(S)H; -OC(S)OH; -OC(SO2)H; -S(O2)NH2; -S(O)NH2; -SNH2; -NHCS(O2)H; -NHC(SO)H; -NHC(S)H; y -SH, sin substituir o substituido con uno o más substituyentes seleccionados entre el grupo compuesto por halógenos; =O; =S; -CN; -NO2; alcano, ramificado o no ramificado; alquilo; heteroalquilo; alquenilo; alquinilo; arilo; cicloalquilo; heterocicloalquilo; heteroarilo; alcoxi; -(CH2)zCN donde z es un entero de 1 a 4; =NH; -NHOH; -OH; -C(O)H; -OC(O)H; -C(O)OH; -C(O)OC(CH3)n, donde n es un entero de 1 a 3; -OC(O)OH; -OC(O)OC(O)H; -OOH; -C(NH)NH2; -NHC(NH)NH2; -C(S)NH2; -NHC(S)NH2; -NHC(O)NH2; -S(O2)H; -S(O)H; -NH2; -C(O)NH2; -OC(O)NH2; -NHC(O)H; -NHC(O)OH; -C(O)NHC(O)H; -OS(O2)H; -OS(O)H; -OSH; -SC(O)H; -SCH2CH3; -S(O)C(O)OH; -SO2C(O)OH; -NHSH; -NHS(O)H; -NHSO2H; -C(O)SH; -C(O)S(O)H; -C(O)S(O2)H; -C(S)H; -C(SO)OH; -C(SO2)OH; -NHC(S)H; -OC(S)H; -OC(S)OH; -OC(SO2)H; -S(O2)NH2; -S(O)NH2; -SNH2; -NHCS(O2)H; -NHC(SO)H; -NHC(S)H; y -SH, sin substituir o substituido con uno o más substituyentes seleccionados entre el grupo compuesto por halógenos; fenilo; cicloalcano; -O-; -OH; y CH3; R4 es =O ó -OR5; X-W es C-CH cuando R4 es =O, y X-W es C=C cuando R4 es -OR5; o R3 y R4 junto con X y W forman un grupo cicloalquilo, heteroarilo, cicloalquilo, o heterocicloalquilo sin substituir o substituidos con uno o más substituyentes seleccionados entre el grupo compuesto por halógenos; =O; =S; -CN; -NO2; alquilo; heteroalquilo; alquenilo; alquinilo; arilo; cicloalquilo; heterocicloalquilo; heteroarilo; alcoxi; isopropilo; t-butilo; -(CH2)zCN donde z es un entero de 1 a 4; =NH; -NHOH; -OH; -OCH3, -OCH2-; -OCH2CH3; -C(O)H; -OC(O)H; -C(O)OH; -CH2CH(O)OCH3; -OC(O)OH; -OC(O)OC(O)H; -OOH; -C(NH)NH2; -NHC(NH)NH2; -C(S)NH2; -NHC(S)NH2; -NHC(O)NH2; -S(O2)H; -S(O)H; -NH2; -C(O)NH2; -OC(O)NH2; -NHC(O)H; -NHC(O)OH; -NHC(NH)NH2; -C(S)NH2; -NHC(S)NH2; -NHC(O)NH2; -S(O2)H; -S(O)H; -NH2; -C(O)NH2; -OC(O)NH2; -NHC(O)H; -NHC(O)OH; -C(O)NHC(O)H; -OS(O2)H; -OS(O)H; -OSH; -SC(O)H; -S(O)C(O)OH; -SO2C(O)OH; -SO2CH3; -NHSH; -NHS(O)H; -NHSO2H; -C(O)SH; -C(O)S(O)H; -C(O)S(O2)H; -C(S)OH; -C(SO)OH; -C (SO2)OH; -NHC(S)H; -OC(S)H; -OC(S)OH; -OC(SO2)H; -S(O2)NH2; -S(O)NH2; -SNH2; -NHCS(O2)H; -NHC(SO)H; -NHC(S)H; y -SH, sin substituir o substituidos con uno o más substituyentes seleccionados entre el grupo compuesto por halógenos; =O; =S; -CN; -NO2; alcano, ramificado o no ramificado; alquilo; heteroalquilo; alquenilo; alquinilo; arilo; cicloalquilo; heterocicloalquilo; heteroarilo; alcoxi; -(CH2)zCN donde z es un entero de 1 a 4; =NH; -NHOH; -OH; -C(O)H; -OC(O)H; -C(O)OH; -C(O)OC(CH3)n, donde n es un entero de 1 a 3; -OC(O)OH; -OC(O)OC(O)H; -OOH; -C(NH)NH2; -NHC(NH)NH2; -C(S)NH2; -NHC(S)NH2; -NHC(O)NH2; -S(O2)H; -S(O)H; -NH2; -C(O)NH2; -OC(O)NH2; -NHC(O)H; -NHC(O)OH; -C(O)NHC(O)H; -OS(O2)H; -OS(O)H; -OSH; -SC(O)H; -SCH2CH3; -S(O)C(O)OH; -SO2C(O)OH; -NHSH; -NHS(O)H; -NHSO2H; -C(O)SH; -C (O)S(O)H; -C(O)S(O2)H; -C(S)H; -C(SO)OH; -C(SO2)OH; -NHC(S)H; -OC(S)H; -OC(S)OH; -OC(SO2)H; -S(O2)NH2; -S(O)NH2; -SNH2; -NHCS(O2)H; -NHC(SO)H; -NHC(S)H; y -SH sin substituir o substituido con uno o más substituyentes seleccionados entre el grupo compuesto por halógenos; arilo; cicloalquilo; -OR5; haloalquilo; y alquilo; y R5 es un alquilo o H.
AR20030101630A 2002-05-10 2003-05-09 Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan AR040411A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37943302P 2002-05-10 2002-05-10

Publications (1)

Publication Number Publication Date
AR040411A1 true AR040411A1 (es) 2005-04-06

Family

ID=29420530

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030101630A AR040411A1 (es) 2002-05-10 2003-05-09 Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan

Country Status (10)

Country Link
US (1) US7115658B2 (es)
AR (1) AR040411A1 (es)
AU (1) AU2003224371A1 (es)
DO (1) DOP2003000641A (es)
GT (1) GT200300105A (es)
PA (1) PA8573401A1 (es)
PE (1) PE20040472A1 (es)
TW (1) TW200306813A (es)
UY (1) UY27798A1 (es)
WO (1) WO2003095441A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
BRPI0507861A (pt) 2004-02-20 2007-07-17 Boehringer Ingelheim Int inibidores de polimerase viral
GEP20094751B (en) * 2004-08-18 2009-08-10 Pfizer Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
MX2007005177A (es) 2004-10-29 2007-06-26 Schering Corp 5-oxo pirazoles y [1,2,4]triazoles sustituidos como agentes antivirales.
CA2619077C (en) 2005-08-24 2011-09-13 Pfizer Inc. Methods for the preparation of hcv polymerase inhibitors
RU2401268C2 (ru) * 2005-08-24 2010-10-10 Пфайзер Инк. КРИСТАЛЛИЧЕСКАЯ ФОРМА (R)-6-ЦИКЛОПЕНТИЛ-6-(2-(2,6-ДИЭТИЛПИРИДИН-4-ИЛ)ЭТИЛ)-3-((5,7-ДИМЕТИЛ-[1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-2-ИЛ)МЕТИЛ)-4-ГИДРОКСИ-5,6-ДИГИДРОПИРАН-2-ОНА, ЕЕ ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЕЕ
DK2320905T3 (en) 2008-08-11 2017-09-18 Glaxosmithkline Llc Corp Service Company New adenine derivatives
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2010018131A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
PL2534149T3 (pl) 2010-02-10 2015-03-31 Glaxosmithkline Llc Maleinian 6-amino-2-{[(1s)-1-metylobutylo]oksy}-9-[5-(1-piperydynylo)pentylo]-7,9-dihydro-8h-puryn-8-onu
EP3107915B1 (en) 2014-02-20 2017-11-08 Glaxosmithkline Intellectual Property (No. 2) Limited Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon
CA2967248A1 (en) 2014-11-13 2016-05-19 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
HK1250032A1 (zh) 2015-12-03 2018-11-23 Glaxosmithkline Intellectual Property Development Limited 作为sting调节剂的环状嘌呤二核苷酸
MX387354B (es) 2016-04-07 2025-03-18 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas.
CN109563081A (zh) 2016-04-07 2019-04-02 葛兰素史克知识产权开发有限公司 可用作蛋白调节剂的杂环酰胺类
US11377440B2 (en) 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
EP3692033A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
CN114391015A (zh) 2019-05-16 2022-04-22 斯汀塞拉股份有限公司 苯并[b][1,8]萘啶乙酸衍生物和使用方法
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CA3164751A1 (en) 2019-12-18 2021-06-24 Benjamin Joseph MORROW Compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786063A (en) * 1971-05-24 1974-01-15 Universal Oil Prod Co Thiazolethiosulfonates
CA1144937A (en) * 1977-12-22 1983-04-19 Dke J.E. Helgstrand Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
US4326058A (en) * 1979-02-05 1982-04-20 Sumitomo Chemical Company, Limited Organo-phosphoric esters and their production and use
US4489077A (en) * 1983-03-23 1984-12-18 Warner-Lambert Company 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
ZA938019B (en) * 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
CA2167537A1 (en) * 1993-07-19 1995-02-02 Tsuneo Ozeki Hepatitis c virus proliferation inhibitor
DE69433705T2 (de) 1993-11-19 2005-03-10 Parke, Davis & Company 5,6-Dihydropyronderivate als Proteaseinhibitoren und Antiviralmittel
US5840751A (en) * 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
EP0729463B1 (en) * 1993-11-19 2002-05-22 PARKE DAVIS & COMPANY 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US5504104A (en) * 1993-11-19 1996-04-02 Warner-Lambert Company Tricyclic pyrone derivatives as protease inhibitors and antiviral agents
US5808062A (en) * 1993-11-19 1998-09-15 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
US5834506A (en) * 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
WO1999014210A1 (en) * 1997-09-15 1999-03-25 Warner-Lambert Company Process for the preparation of substituted 5,6-dihydro-2h-pyran-2-ones
EP1112269A2 (en) * 1998-09-11 2001-07-04 Warner-Lambert Company Hiv protease inhibitors
CA2358438A1 (en) * 1999-01-07 2000-07-13 David Thomas Dudley Antiviral method using mek inhibitors
US6512006B1 (en) * 1999-12-09 2003-01-28 Warner-Lambert Company HIV protease inhibitors
EP1256628A3 (en) * 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
CA2480583C (en) * 2002-04-01 2008-07-15 Pfizer Inc. Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase

Also Published As

Publication number Publication date
AU2003224371A1 (en) 2003-11-11
US7115658B2 (en) 2006-10-03
GT200300105A (es) 2004-03-17
US20040023958A1 (en) 2004-02-05
UY27798A1 (es) 2003-12-31
TW200306813A (en) 2003-12-01
PA8573401A1 (es) 2003-12-10
DOP2003000641A (es) 2003-11-15
WO2003095441A1 (en) 2003-11-20
PE20040472A1 (es) 2004-08-12

Similar Documents

Publication Publication Date Title
AR040411A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan
AR059201A1 (es) Compuestos citotoxicos derivados de tomaimicina
RU2010137808A (ru) Пестицидные композиции
CA2587528A1 (en) Method for preparing n-phenylpyrazole-1-carboxamides
MX2020014087A (es) Moléculas inmunomoduladoras pequeñas novedosas.
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
RU2009139920A (ru) Изоксазолиновые соединения и их применение в борьбе с вредителями
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
PE20040373A1 (es) Composiciones herbicidas que comprenden derivados de isoxazolina
CO5550501A2 (es) Derivados nucleosidos con accion sobre el virus de la hepatitis c, su procedimiento de sintesis y composiciones que los contienen
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
NI200900037A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica.
EA200800476A1 (ru) Макроциклические ингибиторы вируса гепатита с
ES2162466T3 (es) Derivados de 1,2,4-triazolo(4,3-b)pirido(3,2-d)piridazina y composiciones farmaceuticas que los contienen.
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
DK534083D0 (da) 1-carbonyl-1-phenoxyphenyl-2-azolyl-ethanol-derivater, syreadditionssalte, kvaternaere azoliumsalte og metalkomplekser deraf samt deres fremstilling og anvendelse som mikrobicider og plantevaekstregulatorer
DK0412933T3 (da) Overfladebelægningsmaterialer
MX2010002338A (es) Compuesto de organoazufre con fluor y composicion pesticida que lo comprende.
PE20060620A1 (es) Analogos de biaril piperazinil-piridina sustituidos como moduladores del receptor de capsaicina vr1
AR049418A1 (es) Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
RU2015144035A (ru) Способ получения ингибиторов глюкозилцерамидсинтазы
CO5031246A1 (es) Compuestos calciliticos
CL2020002579A1 (es) Compuesto de fenoxiurea y un agente de control de plagas.
PE20251885A1 (es) Composicion nematicida

Legal Events

Date Code Title Description
FA Abandonment or withdrawal